ALC vs PTGX
Alcon Inc vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
65
Buy
| Metric | ALC | PTGX |
|---|
| AI Score |
68
|
65
|
| Price |
$75.39
|
$148.25
|
| P/E Ratio |
45.39×
|
121.74×
|
| ROE |
4.4%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
99.9%
|
| Debt / Equity |
0.24×
|
0.01×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
68.1
|
| Beta |
0.703
|
1.794
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus PTGX.
ALC leads by 3 points.
ALC scores 68/100 (Buy) versus PTGX at 65/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical